This Sentiment Gauge Just Reached Its Most Optimistic Level Since Pre-Covid Days. Time to Buy Stocks?The Motley Fool • 06/29/23
Pfizer wins FDA approval for once-weekly human growth hormone treatment for children aged three and olderMarket Watch • 06/28/23
FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone DeficiencyBusiness Wire • 06/28/23
Pfizer obesity and diabetes drug danuglipron faces major challenges in coming to market, analysts warnProactive Investors • 06/27/23
FDA Accepts Pfizer's Application for Hemophilia B Gene Therapy Fidanacogene ElaparvovecBusiness Wire • 06/27/23
Pfizer Stock Tumbles On 'A Big Setback' In Obesity Treatment Vs. Novo Nordisk, Eli LillyInvestors Business Daily • 06/26/23
Pfizer to advance oral candidate danuglipron as treatment for obesity and diabetes toward late-stage trial and discontinue lotiglipronMarket Watch • 06/26/23